Health Condition 1: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Paediatric oncology patients aged 5-18 years receiving IV Methotrexate
Exclusion criteria
Exclusion criteria: 1. Consent not given 2. Patients having received prior radiotherapy to head/neck region 3. Patients having Diabetes Mellitus. 4. Patients receiving Methotrexate as a part of GVHD prophylaxis for HSCT. 5. Patients with a prior immunosuppressive disorder such as HIV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine and compare the incidence of oral mucositis following IV methotrexate in paediatric oncology patients receiving oral cryotherapy versus standard of care.Timepoint: DAY 5, DAY 14 after recieving IV methotrexate | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine and compare the incidence of febrile neutropenia/infectious complications following IV methotrexate in paediatric oncology patients receiving oral cryotherapy versus standard of care.Timepoint: Day 5, day 14 after recieving IV methotrexate | — |
Countries
India
Contacts
AIIMS, New Delhi